All In Biotech

Drug Trial Radar · NCT06649331

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer:A Prospective, Open-label, Phase 2 Trial

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Sep 2026

Study completion Sep 2027

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.

Conditions

  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Triple Negative Breast Cancer (TNBC)
  • HER2-negative Breast Cancer
  • Breast Cancer

Interventions

  • SHR-A1811Drug

    A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

  • SHR-A1921Drug

    A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.

  • SHR-A2009Drug

    A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.

  • SHR-A2102Drug

    A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.

  • FamitinibDrug

    A VEGFR inhibitor administered orally per the protocol.

  • Fat Module Formula for Special Medical PurposesDietary supplement

    This nutritional formulation is composed primarily of medium-chain triglycerides (MCT), which are metabolized by the liver to induce nutritional ketosis, thereby significantly elevating circulating levels of beta-hydroxybutyrate (BHB).

  • Trastuzumab (or biosimilar)Drug

    An anti-HER2 antibody, via intravenous (into the vein) infusion or subcutaneous per protocol.

  • 9MW2821Drug

    A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.

  • Disitamab Vedotin (RC48)Drug

    A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

  • Treatment of physician's choice (TPC)Drug

    Treatment of physician's choice (TPC), such as nab-paclitaxel, carboplatin, gemcitabine, capecitabine, vinorelbine, eribulin, etc., with specific dosages and administration methods determined at the investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: The observation period related to this endpoint is up to 36 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Breast cancer institute of Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.